Skip to main content

Table 4 Treatment choice - univariate analysis

From: Management of osteoporosis and associated quality of life in post menopausal women

   BP Weekly
N = 462
BP Monthly
N = 388
Strontium Ranelate
N = 182
SERM
N = 115
p Total
N = 1180
Physician speciality Rheumatologists 122 (26.4%) 086 (22.2%) 053 (29.1%) 022 (19.1%) ≤ 0.001 283 (24.7%)
  Gynaecologists 044 (09.5%) 038 (09.8%) 047 (25.8%) 036 (31.3%)   165 (14.4%)
  GPs 296 (64.1%) 264 (68.0%) 082 (45.1%) 057 (49.6%)   699 (60.9%)
Age Mean ± SD 67.3 ± 9.2 66.9 ± 8.1 65.3 ± 9.3 60.00 ± 6.0 ≤ 0.001 66.1 ± 8.9
  Missing data 1 0 1 0   2
Time since menopause (years) Mean ± SD 17.3 ± 9.6 17.2 ± 9.0 15.7 ± 9.8 10.2 ± 6.3 ≤ 0.001 16.3 ± 9.4
  Missing data 5 3 1 3   12
Type of osteoporosis diagnosis Low BMD + osteoporotic fracture 097 (21.0%) 060 (15.5%) 031 (17.0%) 008 (07.0%) ≤ 0.001 196 (17.1%)
  Low BMD without osteoporotic fracture 271 (58.7%) 259 (66.8%) 106 (58.2%) 097 (84.4%)   733 (63.9%)
  Osteoporotic fracture without low BMD 094 (20.4%) 069 (17.8%) 045 (24.7%) 010 (08.7%)   218 (19.0%)
BMD N (%) 391 (84.8%) 331 (86.0%) 159 (87.9%) 108 (93.9%) 0.057 989 (86.6%)
  Missing data 1 3 1 0   5
Mean Hip T-score Mean ± SD -2.24 ± 1.12 -2.34 ± 0.79 -2.33 ± 1.01 -1.81 ± 1.40 0.004 -2.24 ± 1.05
  Missing data 1 1 1 0   3
T-Score by class Normal BMD (Tscore>-1) 1 (0.3%) 0 (0.0%) 1 (0.7%) 000 (00.0%) 0.074 002 (00.2%)
  Osteopenia (-2.5 < Tscore <-1) 30 (8.7%) 16 (05.5%) 7 (5.0%) 012 (13.0%)   065 (07.5%)
  Osteoporosis (Tscore≤-2.5) 313 (91.0%) 275 (94.5%) 131 (94.2%) 080 (87.0%)   799 (92.3%)
  Missing data 47 40 20 16   127
Osteoporotic fractures 230 (51.6%) 169 (46.3%) 95 (54.0%) 27 (25.0%) ≤ 0.001 521 (47.6%)
  Missing data 16 23 6 7   52
   Fractures in the previous 6 months 205 (44.7%) 151 (39.3%) 89 (49.2%) 023 (20.0%) ≤ 0.001 468 (41.1%)
  Missing data 3 4 1 0   8
   Number of fractures in the previous 6 months 1.28 ± 0.62 1.47 ± 0.88 1.40 ± 0.73 1.33 ± 0.58 0.195 1.37 ± 0.74
  Missing data 24 17 6 2   49
Long-term corticosteroid treatment (> 3 months) 47 (10.2%) 36 (9.3%) 11 (6.0%) 5 (4.4%) 0.122 99 (8.6%)
Ongoing treatment at the time of consultation 301 (65.2%) 216 (55.7%) 114 (62.6%) 066 (57.4%) 0.032 697 (60.8%)
Paraclinical investigations   433 (93.7%) 374 (96.6%) 175 (96.2%) 105 (91.3%) 0.057 1087 (94.9%